Targeting iron metabolism in drug discovery and delivery

[1]  Morteza Mahmoudi,et al.  Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. , 2016, Nature nanotechnology.

[2]  C. van Nostrum,et al.  A novel oral iron-complex formulation: Encapsulation of hemin in polymeric micelles and its in vitro absorption. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  M. Knuiman,et al.  Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomes. , 2016, The American journal of clinical nutrition.

[4]  SeJin Kim,et al.  Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  P. Netti,et al.  Energetics of ligand-receptor binding affinity on endothelial cells: An in vitro model. , 2016, Colloids and surfaces. B, Biointerfaces.

[6]  S. Rivella,et al.  Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. , 2016, Blood.

[7]  Xingyu Jiang,et al.  Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[8]  S. Maenosono,et al.  Doxorubicin loaded dual pH- and thermo-responsive magnetic nanocarrier for combined magnetic hyperthermia and targeted controlled drug delivery applications. , 2016, Nanoscale.

[9]  M. Sahay,et al.  A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  S. Reddy,et al.  Apolipoprotein E−/− Mice Lacking Hemopexin Develop Increased Atherosclerosis via Mechanisms That Include Oxidative Stress and Altered Macrophage Function , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[11]  C. Mignogna,et al.  A reappraisal of macrophage polarization in glioblastoma: Histopathological and immunohistochemical findings and review of the literature. , 2016, Pathology, research and practice.

[12]  S. Hemmerich,et al.  Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Herbert Y. Lin,et al.  Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. , 2016, Blood.

[14]  S. Dooley,et al.  Transforming Growth Factor β1 (TGF-β1) Activates Hepcidin mRNA Expression in Hepatocytes* , 2016, The Journal of Biological Chemistry.

[15]  T. Hartman,et al.  Dietary Iron and Colorectal Cancer Risk: A Review of Human Population Studies , 2016, Critical reviews in food science and nutrition.

[16]  C. Enns,et al.  Neogenin Facilitates the Induction of Hepcidin Expression by Hemojuvelin in the Liver* , 2016, The Journal of Biological Chemistry.

[17]  D. Swinkels,et al.  Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects , 2016, British journal of pharmacology.

[18]  J. Bajorath,et al.  En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase‐2 as a Target for Kunitz‐Type Inhibitors , 2016, Chembiochem : a European journal of chemical biology.

[19]  R. Seong,et al.  Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ROS generation. , 2016, Biochemical and biophysical research communications.

[20]  C. D. Savci-Heijink,et al.  A novel gene expression signature for bone metastasis in breast carcinomas , 2016, Breast Cancer Research and Treatment.

[21]  M. Gomez-Lazaro,et al.  Local iron homeostasis in the breast ductal carcinoma microenvironment , 2016, BMC Cancer.

[22]  C. Beaumont,et al.  Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. , 2016, Gastroenterology.

[23]  K. Eckardt,et al.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond , 2016, Nature Reviews Nephrology.

[24]  J. Branco,et al.  Iron overload in a murine model of hereditary hemochromatosis is associated with accelerated progression of osteoarthritis under mechanical stress. , 2016, Osteoarthritis and cartilage.

[25]  Wanjun Zhou,et al.  Human STEAP3 mutations with no phenotypic red cell changes. , 2016, Blood.

[26]  G. Antoni,et al.  Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease , 2016, Nature Communications.

[27]  A. Zuercher,et al.  Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. , 2016, Blood.

[28]  Subramanian Rajagopalan,et al.  Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease , 2016, The Journal of Neuroscience.

[29]  P. Vandenabeele,et al.  Regulated necrosis: disease relevance and therapeutic opportunities , 2016, Nature Reviews Drug Discovery.

[30]  Jodie L Babitt,et al.  Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice. , 2016, Endocrinology.

[31]  Hai Hu,et al.  The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer , 2016, Tumor Biology.

[32]  A. Nordgren,et al.  Mutations in FLVCR2 associated with Fowler syndrome and survival beyond infancy , 2016, Clinical genetics.

[33]  S. Rivella,et al.  Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia , 2016, Haematologica.

[34]  L. Silvestri,et al.  Differing impact of the deletion of hemochromatosis‐associated molecules HFE and transferrin receptor‐2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin , 2016, Hepatology.

[35]  C. Slapak,et al.  Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia , 2015 .

[36]  M. Marsella,et al.  Iron Chelation in Thalassemia Major. , 2015, Clinical therapeutics.

[37]  Toshiro K. Ohsumi,et al.  A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency , 2015, Nature Genetics.

[38]  P. Stattin,et al.  Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions , 2015, Scientific Reports.

[39]  D. Thiele,et al.  Intestinal DMT1 is critical for iron absorption in the mouse but is not required for the absorption of copper or manganese. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[40]  D. di Lorenzo,et al.  Iron and Neurodegeneration: Is Ferritinophagy the Link? , 2015, Molecular Neurobiology.

[41]  O. Nureki,et al.  Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin , 2015, Nature Communications.

[42]  J. Fernández-Real,et al.  Mechanisms Linking Glucose Homeostasis and Iron Metabolism Toward the Onset and Progression of Type 2 Diabetes , 2015, Diabetes Care.

[43]  Nupur K. Das,et al.  Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. , 2015, Cancer cell.

[44]  R. Deberardinis,et al.  Oxidative stress inhibits distant metastasis by human melanoma cells , 2015, Nature.

[45]  A. Joharapurkar,et al.  Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia , 2015, Drug Research.

[46]  Kuanyu Li,et al.  Low expression of ferroxidases is implicated in the iron retention in human atherosclerotic plaques. , 2015, Biochemical and biophysical research communications.

[47]  P. Arosio,et al.  Expression of iron homeostasis proteins in the spinal cord in experimental autoimmune encephalomyelitis and their implications for iron accumulation , 2015, Neurobiology of Disease.

[48]  M. Rosen,et al.  Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats , 2015, British journal of pharmacology.

[49]  J. Reymond,et al.  Discovery and characterization of a novel non-competitive inhibitor of the divalent metal transporter DMT1/SLC11A2. , 2015, Biochemical pharmacology.

[50]  Thomas H Scheuermann,et al.  Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. , 2015, Journal of medicinal chemistry.

[51]  D. Kosman,et al.  Mechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrier , 2015, Front. Mol. Neurosci..

[52]  Elizabeta Nemeth,et al.  Iron homeostasis in host defence and inflammation , 2015, Nature reviews. Immunology.

[53]  Wei Zhang,et al.  SLC39A14 Is Required for the Development of Hepatocellular Iron Overload in Murine Models of Hereditary Hemochromatosis. , 2015, Cell metabolism.

[54]  Shu G. Chen,et al.  Prion protein functions as a ferrireductase partner for ZIP14 and DMT1. , 2015, Free radical biology & medicine.

[55]  T. Rouault.  Iron-sulfur proteins hiding in plain sight. , 2015, Nature chemical biology.

[56]  Jonghan Kim,et al.  The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[57]  L. Miller,et al.  Hepcidin regulation in prostate and its disruption in prostate cancer. , 2015, Cancer research.

[58]  D. Kosman,et al.  Molecular mechanisms of non‐transferrin‐bound and transferring‐bound iron uptake in primary hippocampal neurons , 2015, Journal of neurochemistry.

[59]  Keith A. Johnson,et al.  Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE , 2015, Nature Communications.

[60]  T. Akizawa,et al.  FP380JTZ-951, AN ORAL NOVEL HIF-PHD INHIBITOR, ELEVATES HEMOGLOBIN IN JAPANESE ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS , 2015 .

[61]  V. Kosma,et al.  High numbers of macrophages, especially M2‐like (CD163‐positive), correlate with hyaluronan accumulation and poor outcome in breast cancer , 2015, Histopathology.

[62]  C. H. Bell,et al.  Repulsive Guidance Molecule is a structural bridge between Neogenin and Bone Morphogenetic Protein , 2015, Nature Structural &Molecular Biology.

[63]  Jing-Wei Zhao,et al.  Expression and cellular localization of hepcidin mRNA and protein in normal rat brain , 2015, BMC Neuroscience.

[64]  P. Apostoli,et al.  Bmp6 Expression in Murine Liver Non Parenchymal Cells: A Mechanism to Control their High Iron Exporter Activity and Protect Hepatocytes from Iron Overload? , 2015, PloS one.

[65]  S Aime,et al.  Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. , 2015, Nanoscale.

[66]  I. Yanatori,et al.  Inhibition of iron uptake by ferristatin II is exerted through internalization of DMT1 at the plasma membrane , 2015, Cell biology international.

[67]  S. Rivella.  β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies , 2015, Haematologica.

[68]  C. Lacombe,et al.  Regulation of cell surface transferrin receptor-2 by iron-dependent cleavage and release of a soluble form , 2015, Haematologica.

[69]  Tie-mei Shao,et al.  Age-related changes of brain iron load changes in the frontal cortex in APPswe/PS1ΔE9 transgenic mouse model of Alzheimer's disease. , 2015, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[70]  W. Gu,et al.  Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.

[71]  Haichao Wang,et al.  HSPB1 as a Novel Regulator of Ferroptotic Cancer Cell Death , 2015, Oncogene.

[72]  Alexander Böker,et al.  Ferritin: a versatile building block for bionanotechnology. , 2015, Chemical reviews.

[73]  J. Abkowitz,et al.  Heme Exporter FLVCR Is Required for T Cell Development and Peripheral Survival , 2015, The Journal of Immunology.

[74]  G. Weiss,et al.  'Ride on the ferrous wheel'--the cycle of iron in macrophages in health and disease. , 2015, Immunobiology.

[75]  P. Murray,et al.  Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer , 2015, Nature Medicine.

[76]  Blaine R. Roberts,et al.  Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. , 2015, ACS chemical neuroscience.

[77]  E. Valore,et al.  Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. , 2015, Cell host & microbe.

[78]  J. Connor,et al.  A Novel Model for Brain Iron Uptake: Introducing the Concept of Regulation , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[79]  M. Hentze,et al.  A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. , 2014, Blood.

[80]  A. Walch,et al.  Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice , 2014, Nature Cell Biology.

[81]  D. Green,et al.  Synchronized renal tubular cell death involves ferroptosis , 2014, Proceedings of the National Academy of Sciences.

[82]  Daoqiang Zhang,et al.  Disordered hepcidin-ferroportin signaling promotes breast cancer growth. , 2014, Cellular signalling.

[83]  N. Faux,et al.  An anemia of Alzheimer's disease , 2014, Molecular Psychiatry.

[84]  P. Schumacker,et al.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.

[85]  M. F. Aslam,et al.  A Nanoparticulate Ferritin-Core Mimetic Is Well Taken Up by HuTu 80 Duodenal Cells and Its Absorption in Mice Is Regulated by Body Iron12 , 2014, The Journal of nutrition.

[86]  D. Swinkels,et al.  Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. , 2014, Blood.

[87]  R. Dutzler,et al.  Crystal structure of a SLC11 (NRAMP) transporter reveals the basis for transition-metal ion transport , 2014, Nature Structural &Molecular Biology.

[88]  T. Ganz,et al.  Erythroferrone contributes to recovery from anemia of inflammation. , 2014, Blood.

[89]  Kuo Yang,et al.  Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress , 2014, Oncogene.

[90]  Jeff H Duyn,et al.  The role of iron in brain ageing and neurodegenerative disorders , 2014, The Lancet Neurology.

[91]  Jan Grimm,et al.  Nanoparticles for imaging: top or flop? , 2014, Radiology.

[92]  M. Gaestel,et al.  TNF and Increased Intracellular Iron Alter Macrophage Polarization to a Detrimental M1 Phenotype in the Injured Spinal Cord , 2014, Neuron.

[93]  W. Nyka,et al.  Changes in skeletal muscle iron metabolism outpace amyotrophic lateral sclerosis onset in transgenic rats bearing the G93A hmSOD1 gene mutation , 2014, Free radical research.

[94]  DuhamelAlain,et al.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .

[95]  P. A. Lay,et al.  Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes. , 2014, Human molecular genetics.

[96]  S. Rivella,et al.  IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.

[97]  M. Kaul,et al.  Cellular protection using Flt3 and PI3Kα inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity , 2014, Nature Communications.

[98]  S. Gygi,et al.  Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy , 2014, Nature.

[99]  D. Girelli,et al.  Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. , 2014, Blood.

[100]  B. Stockwell,et al.  Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models , 2014, Journal of the American Chemical Society.

[101]  S. Rivella,et al.  Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. , 2014, Blood.

[102]  W. Griffin,et al.  Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease , 2014, Acta neuropathologica communications.

[103]  M. Daidone,et al.  Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  L. Kiemeney,et al.  Serum Hepcidin Is Associated With Presence of Plaque in Postmenopausal Women of a General Population , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[105]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[106]  A. Lusis,et al.  Testing the iron hypothesis in a mouse model of atherosclerosis. , 2013, Cell reports.

[107]  V. Wroblewski,et al.  LY2928057, An Antibody Targeting Ferroportin, Is a Potent Inhibitor Of Hepcidin Activity and Increases Iron Mobilization In Normal Cynomolgus Monkeys , 2013 .

[108]  Chi-kong Li,et al.  A Possible Role Of The Tetraspanin CD9 In Bone Marrow Retention and Engraftment Of Human CD34+ Hematopoietic Stem/Progenitor Cells , 2013 .

[109]  S. Haulon,et al.  Liver X Receptor Activation Stimulates Iron Export in Human Alternative Macrophages , 2013, Circulation research.

[110]  S. Rivella,et al.  Cancer cells with irons in the fire. , 2013, Free radical biology & medicine.

[111]  C. Begley,et al.  A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. , 2013, Blood.

[112]  J. Abkowitz,et al.  FLVCR is necessary for erythroid maturation, may contribute to platelet maturation, but is dispensable for normal hematopoietic stem cell function. , 2013, Blood.

[113]  R. Kok,et al.  Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. , 2013, Advanced drug delivery reviews.

[114]  T. Ganz.  Systemic iron homeostasis. , 2013, Physiological reviews.

[115]  C. Férec,et al.  Structure‐Function Analysis of the Human Ferroportin Iron Exporter (SLC40A1): Effect of Hemochromatosis Type 4 Disease Mutations and Identification of Critical Residues , 2013, Human mutation.

[116]  Radhika A. Vaishnav,et al.  The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease , 2013, Acta neuropathologica communications.

[117]  Robert T. Means,et al.  Iron deficiency anemia , 2013, Hematology.

[118]  M. Muckenthaler,et al.  Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome , 2013, The Journal of experimental medicine.

[119]  Victoria Tapia,et al.  Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells , 2013, Journal of neurochemistry.

[120]  E. Fraenkel,et al.  The small molecule, genistein, increases hepcidin expression in human hepatocytes , 2013, Hepatology.

[121]  Jonghan Kim,et al.  Ferristatin II Promotes Degradation of Transferrin Receptor-1 In Vitro and In Vivo , 2013, PloS one.

[122]  Tracy J. Yuen,et al.  M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination , 2013, Nature Neuroscience.

[123]  C. H. Bell,et al.  Structure of the Repulsive Guidance Molecule (RGM)–Neogenin Signaling Hub , 2013, Science.

[124]  T. Rouault,et al.  Iron metabolism in the CNS: implications for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[125]  R. MacGillivray,et al.  Multi-Copper Oxidases and Human Iron Metabolism , 2013, Nutrients.

[126]  P. Libby,et al.  Local proliferation dominates lesional macrophage accumulation in atherosclerosis , 2013, Nature Medicine.

[127]  L. Lartigue,et al.  Biodegradation of iron oxide nanocubes: high-resolution in situ monitoring. , 2013, ACS nano.

[128]  Mark E. Davis,et al.  Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor , 2013, Proceedings of the National Academy of Sciences.

[129]  G. Elmberger,et al.  Progressive reactive lymphoid connective tissue disease and development of autoantibodies in scavenger receptor A5-deficient mice. , 2013, The American journal of pathology.

[130]  Antonina Rait,et al.  Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[131]  F. Torti,et al.  Iron and cancer: more ore to be mined , 2013, Nature Reviews Cancer.

[132]  G. Schett,et al.  Anaemia in inflammatory rheumatic diseases , 2013, Nature Reviews Rheumatology.

[133]  S. Rivella,et al.  Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. , 2013, The Journal of clinical investigation.

[134]  A. Bergman,et al.  CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress , 2013, Nature Medicine.

[135]  David Pitt,et al.  Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions , 2013, PloS one.

[136]  R. Damoiseaux,et al.  High-Throughput Screening of Small Molecules Identifies Hepcidin Antagonists , 2013, Molecular Pharmacology.

[137]  S. Rivella,et al.  Macrophages support pathological erythropoiesis in Polycythemia Vera and Beta-Thalassemia , 2013, Nature Medicine.

[138]  S. Milstein,et al.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. , 2013, Blood.

[139]  M. Fleming,et al.  HRG1 is essential for heme transport from the phagolysosome of macrophages during erythrophagocytosis. , 2013, Cell metabolism.

[140]  Rui Chen,et al.  Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules , 2013, Nature chemical biology.

[141]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[142]  G. Merlo,et al.  The mitochondrial heme exporter FLVCR1b mediates erythroid differentiation. , 2012, The Journal of clinical investigation.

[143]  Hong-Kyu Kim,et al.  Iron overload accelerates bone loss in healthy postmenopausal women and middle‐aged men: A 3‐year retrospective longitudinal study , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[144]  M. Hentze,et al.  The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. , 2012, Journal of hepatology.

[145]  A. Aydın,et al.  Premature Atherosclerosis in Children With &bgr;-Thalassemia Major , 2012, Journal of pediatric hematology/oncology.

[146]  T. Ganz,et al.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. , 2012, Blood.

[147]  M. Arno,et al.  Duodenal reductase activity and spleen iron stores are reduced and erythropoiesis is abnormal in Dcytb knockout mice exposed to hypoxic conditions. , 2012, The Journal of nutrition.

[148]  S. Wild,et al.  Ferritin Is Independently Associated With the Presence of Coronary Artery Calcium in 12 033 Men , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[149]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[150]  S. Moestrup,et al.  Structure of the haptoglobin–haemoglobin complex , 2012, Nature.

[151]  M. Knutson,et al.  ZIP8 Is an Iron and Zinc Transporter Whose Cell-surface Expression Is Up-regulated by Cellular Iron Loading* , 2012, The Journal of Biological Chemistry.

[152]  A. Ganser,et al.  Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial , 2012, Anemia.

[153]  Y. P. Goldberg,et al.  Discovery of benzylisothioureas as potent divalent metal transporter 1 (DMT1) inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[154]  M. Desjardins,et al.  Subcellular Localization of Iron and Heme Metabolism Related Proteins at Early Stages of Erythrophagocytosis , 2012, PloS one.

[155]  A. Waheed,et al.  Ferritin upregulates hepatic expression of bone morphogenetic protein 6 and hepcidin in mice. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[156]  Vladimir P Torchilin,et al.  Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[157]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[158]  Kai Zhang,et al.  Hepcidin Destabilizes Atherosclerotic Plaque Via Overactivating Macrophages After Erythrophagocytosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[159]  M. Baraibar,et al.  A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage. , 2012, Free radical biology & medicine.

[160]  D. Lee,et al.  Associations of Serum Ferritin and Transferrin % Saturation With All-cause, Cancer, and Cardiovascular Disease Mortality: Third National Health and Nutrition Examination Survey Follow-up Study , 2012, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[161]  C. Santos,et al.  STEAP Proteins: From Structure to Applications in Cancer Therapy , 2012, Molecular Cancer Research.

[162]  D. Leake,et al.  Oxidation of Low-Density Lipoprotein by Iron at Lysosomal pH: Implications for Atherosclerosis , 2012, Biochemistry.

[163]  S. Biswas,et al.  Macrophage polarization and plasticity in health and disease , 2012, Immunologic research.

[164]  L. Game,et al.  Activating Transcription Factor 1 Directs Mhem Atheroprotective Macrophages Through Coordinated Iron Handling and Foam Cell Protection , 2012, Circulation research.

[165]  J. Bajorath,et al.  Insights into Matriptase‐2 Substrate Binding and Inhibition Mechanisms by Analyzing Active‐Site‐Mutated Variants , 2012, ChemMedChem.

[166]  K. Ray,et al.  The biology and chemistry of high-valent iron–oxo and iron–nitrido complexes , 2012, Nature Communications.

[167]  H. Heimpel,et al.  A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. , 2011, Blood.

[168]  Shuping Zhang,et al.  AG490: an inhibitor of hepcidin expression in vivo. , 2011, World journal of gastroenterology.

[169]  Elizabeta Nemeth,et al.  Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. , 2011, The Journal of clinical investigation.

[170]  B. Bettencourt,et al.  Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia , 2011 .

[171]  Suzy V. Torti,et al.  An iron regulatory gene signature predicts outcome in breast cancer. , 2011, Cancer research.

[172]  K. Akashi,et al.  Human STEAP3 maintains tumor growth under hypoferric condition. , 2011, Experimental cell research.

[173]  D. Richardson,et al.  Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer , 2011, Molecular Pharmacology.

[174]  A. Kraneveld,et al.  Macrophages and liposomes in inflammatory disease: friends or foes? , 2011, International journal of pharmaceutics.

[175]  G. Anderson,et al.  Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. , 2011, Blood.

[176]  Yuzhang Wu,et al.  Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains , 2011, Journal of Neuroimmunology.

[177]  M. Wendland,et al.  MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles , 2011, Clinical Cancer Research.

[178]  C. López-Otín,et al.  Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. , 2011, Blood.

[179]  Y. Ke,et al.  Divalent metal transporter 1 is a hypoxia‐inducible gene , 2011, Journal of cellular physiology.

[180]  Chunyu Wang,et al.  Structure and metal ion binding of the first transmembrane domain of DMT1. , 2011, Biochimica et biophysica acta.

[181]  F. Gonzalez,et al.  Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. , 2011, Gastroenterology.

[182]  B. Paw,et al.  Targeted deletion of the mouse Mitoferrin1 gene: from anemia to protoporphyria. , 2011, Blood.

[183]  T. Hirano,et al.  The Zinc Transporter SLC39A14/ZIP14 Controls G-Protein Coupled Receptor-Mediated Signaling Required for Systemic Growth , 2011, PloS one.

[184]  Cord Sunderkötter,et al.  An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. , 2011, The Journal of clinical investigation.

[185]  L. N. Valenti,et al.  Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[186]  G. Kovtunovych,et al.  Dysfunction of the heme recycling system in heme oxygenase 1-deficient mice: effects on macrophage viability and tissue iron distribution. , 2010, Blood.

[187]  C. Tailor,et al.  The Fowler Syndrome-Associated Protein FLVCR2 Is an Importer of Heme , 2010, Molecular and Cellular Biology.

[188]  M. Hentze,et al.  Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. , 2010, Blood.

[189]  Douglas B. Kell,et al.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples , 2010, Archives of Toxicology.

[190]  M. Willingham,et al.  Ferroportin and iron regulation in breast cancer progression and prognosis. , 2010, Science translational medicine.

[191]  F. Bou-Abdallah,et al.  The iron redox and hydrolysis chemistry of the ferritins. , 2010, Biochimica et biophysica acta.

[192]  J. Bajorath,et al.  Identification of the first low-molecular-weight inhibitors of matriptase-2. , 2010, Journal of medicinal chemistry.

[193]  R. Strong,et al.  Iron Traffics in Circulation Bound to a Siderocalin (Ngal)-Catechol Complex , 2010, Nature chemical biology.

[194]  Silvia Deaglio,et al.  Transferrin receptor 2 is frequently and highly expressed in glioblastomas. , 2010, Translational oncology.

[195]  H. Nauwynck,et al.  Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. , 2010, Molecular immunology.

[196]  M. Cappellini,et al.  Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. , 2010, Blood.

[197]  V. Barton,et al.  The Molecular Mechanism of Action of Artemisinin—The Debate Continues , 2010, Molecules.

[198]  C. Scudamore,et al.  Human hephaestin expression is not limited to enterocytes of the gastrointestinal tract but is also found in the antrum, the enteric nervous system, and pancreatic {beta}-cells. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[199]  W. Seaman,et al.  Binding and uptake of H-ferritin are mediated by human transferrin receptor-1 , 2010, Proceedings of the National Academy of Sciences.

[200]  P. Brissot,et al.  Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form , 2010, Journal of Molecular Medicine.

[201]  Charles B. Hall,et al.  Transferrin therapy ameliorates disease in β-thalassemic mice , 2010, Nature Medicine.

[202]  G. Anderson,et al.  Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload , 2009, Hepatology.

[203]  J. Sullivan.  Do Hemochromatosis Mutations Protect Against Iron-Mediated Atherogenesis? , 2009, Circulation. Cardiovascular genetics.

[204]  P. Gros,et al.  Transmembrane Topology of the Mammalian Slc11a2 Iron Transporter , 2009, Biochemistry.

[205]  T. Ganz,et al.  The molecular basis of hepcidin-resistant hereditary hemochromatosis. , 2009, Blood.

[206]  R. Leduc,et al.  Probing the substrate specificities of matriptase, matriptase‐2, hepsin and DESC1 with internally quenched fluorescent peptides , 2009, The FEBS journal.

[207]  Neena Singh,et al.  Abnormal Brain Iron Homeostasis in Human and Animal Prion Disorders , 2009, PLoS pathogens.

[208]  M. Roth,et al.  Lack of the bone morphogenetic protein BMP6 induces massive iron overload , 2009, Nature Genetics.

[209]  J. Stark,et al.  Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. , 2009, The American journal of pathology.

[210]  Yin Xia,et al.  BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism , 2009, Nature Genetics.

[211]  F. Gonzalez,et al.  Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. , 2009, Cell metabolism.

[212]  M. Wessling-Resnick,et al.  Small molecule inhibitors of divalent metal transporter-1. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[213]  Simone Sanna-Cherchi,et al.  Scara5 is a ferritin receptor mediating non-transferrin iron delivery. , 2009, Developmental cell.

[214]  Jerry Kaplan,et al.  The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. , 2008, Cell metabolism.

[215]  Charles Duyckaerts,et al.  Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[216]  J. Dick,et al.  Enhanced alternative splicing of the FLVCR1 gene in Diamond Blackfan anemia disrupts FLVCR1 expression and function that are critical for erythropoiesis , 2008, Haematologica.

[217]  W. Jiang,et al.  Genetic upregulation of matriptase‐2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation , 2008, Journal of cellular physiology.

[218]  D. Kell.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases , 2008, BMC Medical Genomics.

[219]  Randall T Peterson,et al.  Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[220]  M. Wessling-Resnick,et al.  The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor. , 2008, Chemistry & biology.

[221]  Wei Li,et al.  Overexpression of Transferrin Receptor and Ferritin Related to Clinical Symptoms and Destabilization of Human Carotid Plaques , 2008, Experimental biology and medicine.

[222]  B. Paw,et al.  Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins , 2008, Nature.

[223]  B. Beutler,et al.  The Serine Protease TMPRSS6 Is Required to Sense Iron Deficiency , 2008, Science.

[224]  N. Andrews,et al.  Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA) , 2008, Nature Genetics.

[225]  N. Andrews,et al.  The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. , 2008, Cell metabolism.

[226]  J. Abkowitz,et al.  A Heme Export Protein Is Required for Red Blood Cell Differentiation and Iron Homeostasis , 2008, Science.

[227]  A. Mckie,et al.  Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. , 2007, The Journal of nutrition.

[228]  V. Nizet,et al.  Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). , 2007, The Journal of clinical investigation.

[229]  S. Robinson,et al.  The Pivotal Role of Astrocytes in the Metabolism of Iron in the Brain , 2007, Neurochemical Research.

[230]  Junxia Xie,et al.  Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6‐OHDA‐lesioned rats , 2007, The European journal of neuroscience.

[231]  Mayka Sanchez,et al.  Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency , 2007, Nature Structural &Molecular Biology.

[232]  M. Linton,et al.  Deletion of Macrophage LDL Receptor–Related Protein Increases Atherogenesis in the Mouse , 2007, Circulation research.

[233]  S. Ha,et al.  Carotid intima‐media thickness is increased and related to arterial stiffening in patients with beta‐thalassaemia major , 2006, British journal of haematology.

[234]  R. Cousins,et al.  Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells , 2006, Proceedings of the National Academy of Sciences.

[235]  K. Takeda,et al.  Placental but Not Heart Defects Are Associated with Elevated Hypoxia-Inducible Factor α Levels in Mice Lacking Prolyl Hydroxylase Domain Protein 2 , 2006, Molecular and Cellular Biology.

[236]  M. Wessling-Resnick,et al.  Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. , 2006, Chemistry & biology.

[237]  M. Fleming,et al.  The Steap proteins are metalloreductases. , 2006, Blood.

[238]  J. Zondlo,et al.  Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[239]  K. Davies,et al.  Identification and Characterization of Murine SCARA5, a Novel Class A Scavenger Receptor That Is Expressed by Populations of Epithelial Cells* , 2006, Journal of Biological Chemistry.

[240]  G. Berx,et al.  Modulation of iron transport proteins in human colorectal carcinogenesis , 2006, Gut.

[241]  Raymond T Chung,et al.  Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression , 2006, Nature Genetics.

[242]  A. Brownlie,et al.  Mitoferrin is essential for erythroid iron assimilation , 2006, Nature.

[243]  M. McMullin,et al.  A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[244]  E. Stadtman.  Protein oxidation and aging , 2006, Science.

[245]  R. MacGillivray,et al.  Recombinant expression and functional characterization of human hephaestin: a multicopper oxidase with ferroxidase activity. , 2005, Biochemistry.

[246]  J. J. Sharp,et al.  Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells , 2005, Nature Genetics.

[247]  N. Andrews,et al.  Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. , 2005, Blood.

[248]  F. Brodsky,et al.  TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis , 2005, The Journal of experimental medicine.

[249]  P. Højrup,et al.  Identification of the receptor scavenging hemopexin-heme complexes. , 2005, Blood.

[250]  T. Aleman,et al.  Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. , 2005, Ophthalmology.

[251]  N. Andrews,et al.  Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. , 2005, The Journal of clinical investigation.

[252]  A. Donovan,et al.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. , 2005, Cell metabolism.

[253]  J. Prchal,et al.  Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. , 2005, Blood.

[254]  R. Nicholson,et al.  Structure–function analysis of a novel member of the LIV‐1 subfamily of zinc transporters, ZIP14 , 2005, FEBS letters.

[255]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[256]  Shizuo Akira,et al.  Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron , 2004, Nature.

[257]  J. Connor,et al.  Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences , 2004, Journal of the Neurological Sciences.

[258]  E. Beutler,et al.  Molecular characterization of a third case of human atransferrinemia. , 2004, Blood.

[259]  J. Abkowitz,et al.  Identification of a Human Heme Exporter that Is Essential for Erythropoiesis , 2004, Cell.

[260]  P. Delepelaire,et al.  Bacterial iron sources: from siderophores to hemophores. , 2004, Annual review of microbiology.

[261]  Y. Niitsu.  A ride on the ferrous wheel , 2004, Cancer biology & therapy.

[262]  W. Bartfay,et al.  Ebselen Decreases Oxygen Free Radical Production and Iron Concentrations in the Hearts of Chronically Iron-Overloaded Mice , 2004, Biological research for nursing.

[263]  M. Davies,et al.  Direct Detection and Quantification of Transition Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of Elevated Levels of Iron and Copper , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[264]  Elizabeta Nemeth,et al.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.

[265]  V. Subramaniam,et al.  Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. , 2004, Journal of hepatology.

[266]  Sharmistha Ghosh,et al.  Regulated secretion of glycosylated human ferritin from hepatocytes. , 2004, Blood.

[267]  D. Haskard,et al.  Hemoglobin Scavenger Receptor CD163 Mediates Interleukin-10 Release and Heme Oxygenase-1 Synthesis: Antiinflammatory Monocyte-Macrophage Responses In Vitro, in Resolving Skin Blisters In Vivo, and After Cardiopulmonary Bypass Surgery , 2004, Circulation research.

[268]  Kan Ding,et al.  Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1−/− mice , 2003, Nature Genetics.

[269]  R. Weissleder,et al.  The transferrin receptor: a potential molecular imaging marker for human cancer. , 2003, Neoplasia.

[270]  C. Ponting,et al.  Stromal cell-derived receptor 2 and cytochrome b561 are functional ferric reductases. , 2003, Biochimica et biophysica acta.

[271]  A. Hofman,et al.  Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism , 2003, Neuroscience Letters.

[272]  S. David,et al.  Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.

[273]  K. Garcia,et al.  Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex , 2003, Science.

[274]  P. Acklin,et al.  Development of tridentate iron chelators: from desferrithiocin to ICL670. , 2003, Current medicinal chemistry.

[275]  E. Zandi,et al.  Iron activates NF-κB in Kupffer cells , 2002 .

[276]  J. Eaton,et al.  Molecular bases of cellular iron toxicity. , 2002, Free radical biology & medicine.

[277]  P. Gros,et al.  Characterization of the iron transporter DMT1 (NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice. , 2001, Blood.

[278]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[279]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[280]  A. Donovan,et al.  Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. , 2001, The Journal of clinical investigation.

[281]  C. Beaumont,et al.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[282]  Cornelia M. van Duijn,et al.  A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis , 2001, Nature Genetics.

[283]  Christina H. Park,et al.  Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.

[284]  R J Simpson,et al.  An Iron-Regulated Ferric Reductase Associated with the Absorption of Dietary Iron , 2001, Science.

[285]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[286]  Peter Schulz-Knappe,et al.  LEAP‐1, a novel highly disulfide‐bonded human peptide, exhibits antimicrobial activity , 2000, FEBS letters.

[287]  S. Abboud,et al.  A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism* , 2000, The Journal of Biological Chemistry.

[288]  Paolo Gasparini,et al.  The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 , 2000, Nature Genetics.

[289]  A. Brownlie,et al.  Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter , 2000, Nature.

[290]  R J Simpson,et al.  A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. , 2000, Molecular cell.

[291]  L. Bianchi,et al.  Transferrin Receptor Induction by Hypoxia , 1999, The Journal of Biological Chemistry.

[292]  H. Koeffler,et al.  Molecular Cloning of Transferrin Receptor 2 , 1999, The Journal of Biological Chemistry.

[293]  J. Connor,et al.  Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains , 1999, Journal of the Neurological Sciences.

[294]  Nancy Andrews,et al.  Transferrin receptor is necessary for development of erythrocytes and the nervous system , 1999, Nature Genetics.

[295]  S. Lynch,et al.  Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients , 1999, Brain Research.

[296]  Gregory J. Anderson,et al.  Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse , 1999, Nature Genetics.

[297]  Yoshihiro Sato,et al.  Cerebrospinal fluid ferritin in glioblastoma: Evidence for tumor synthesis , 1998, Journal of Neuro-Oncology.

[298]  N. Andrews,et al.  Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[299]  S. Tonegawa,et al.  Heme oxygenase 1 is required for mammalian iron reutilization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[300]  N. Andrews,et al.  Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene , 1997, Nature genetics.

[301]  Stephan Nussberger,et al.  Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.

[302]  Steven M LeVine,et al.  Iron deposits in multiple sclerosis and Alzheimer's disease brains , 1997, Brain Research.

[303]  B. Peng,et al.  Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). , 1997, Antisense & nucleic acid drug development.

[304]  S. Lynch,et al.  Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study , 1996, Multiple sclerosis.

[305]  M. C. Ellis,et al.  A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosis , 1996, Nature Genetics.

[306]  O. Zak,et al.  Transferrin receptor‐independent uptake of differic transferrin by human hepatoma cells with antisense inhibition of receptor expression , 1996, Hepatology.

[307]  W. Jefferies,et al.  Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin , 1996, Brain Research.

[308]  J. Connor,et al.  Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.

[309]  G. Koren,et al.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.

[310]  J. Edwardson,et al.  Transferrin receptors in the Parkinsonian midbrain , 1994, Neuropathology and applied neurobiology.

[311]  Y. Agid,et al.  Distribution of 125I‐Ferrotransferrin Binding Sites in the Mesencephalon of Control Subjects and Patients with Parkinson's Disease , 1993, Journal of neurochemistry.

[312]  R. Hammer,et al.  LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation , 1992, Cell.

[313]  R. Kalaria,et al.  Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease , 1992, Brain Research.

[314]  P. Arosio,et al.  Characterization of the ferritin receptors of human T lymphoid (MOLT-4) cells. , 1992, The Journal of laboratory and clinical medicine.

[315]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[316]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[317]  A. Donfrancesco,et al.  Effects of a single course of deferoxamine in neuroblastoma patients. , 1990, Cancer research.

[318]  G. Ebers,et al.  Abnormalities in Iron Metabolism in Multiple Sclerosis , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[319]  M. Hentze,et al.  Binding of a cytosolic protein to the iron-responsive element of human ferritin messenger RNA. , 1988, Science.

[320]  H. Munro,et al.  Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5' untranslated region of ferritin heavy- and light-subunit mRNAs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[321]  A. Ciechanover,et al.  pH and the recycling of transferrin during receptor-mediated endocytosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[322]  P. Aisen,et al.  Stoichiometric and site characteristics of the binding of iron to human transferrin. , 1978, The Journal of biological chemistry.

[323]  H. Keberle.  The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.

[324]  J. Weiß,et al.  Über die Katalyse des Hydroperoxydes , 1932, Naturwissenschaften.

[325]  Zunjin Liu,et al.  Serum iron levels and Parkinson ’ s disease risk : evidence from a meta-analysis , 2016 .

[326]  Diwei Ho,et al.  Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles. , 2016, Small.

[327]  B. Staels,et al.  Macrophage subsets in atherosclerosis , 2015, Nature Reviews Cardiology.

[328]  Daoqiang Zhang,et al.  Disordered signaling governing ferroportin transcription favors breast cancer growth. , 2015, Cellular signalling.

[329]  Lin Hou,et al.  Transferrin-mediated fullerenes nanoparticles as Fe(2+)-dependent drug vehicles for synergistic anti-tumor efficacy. , 2015, Biomaterials.

[330]  B. Stockwell,et al.  The role of iron and reactive oxygen species in cell death. , 2014, Nature Chemical Biology.

[331]  L. Defebvre,et al.  Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .

[332]  Neena Singh,et al.  Prion protein regulates iron transport by functioning as a ferrireductase. , 2013, Journal of Alzheimer's disease : JAD.

[333]  L. Hazrati,et al.  Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy. , 2013, Journal of Parkinson's disease.

[334]  P. Rossini,et al.  Association of K832R and R952K SNPs of Wilson's disease gene with Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[335]  Y. P. Goldberg,et al.  Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1). , 2012, Bioorganic & medicinal chemistry letters.

[336]  M. Mohan,et al.  Prion protein and metal interaction: physiological and pathological implications. , 2010, Current issues in molecular biology.

[337]  G. Ball,et al.  Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen , 2009, Breast Cancer Research and Treatment.

[338]  Charles C Hong,et al.  Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. , 2008, Nature chemical biology.

[339]  Marie-Pierre Dubé,et al.  Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis , 2004, Nature Genetics.

[340]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[341]  D. Loukopoulos,et al.  Arthropathy in juvenile hemochromatosis. , 2003, Arthritis and rheumatism.

[342]  D. Girelli,et al.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis , 2003, Nature Genetics.

[343]  Y. Oda,et al.  Heme oxygenase-1 deficiency: the first autopsy case. , 2002, Human pathology.

[344]  A. Donfrancesco,et al.  Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. , 1995, European journal of cancer.

[345]  K. Krabbe,et al.  Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[346]  M. Pippard.  Iron chelation in thalassemia. , 1988, Birth defects original article series.

[347]  H. Fenton,et al.  LXXIII.—Oxidation of tartaric acid in presence of iron , 1894 .